Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus

Pamela KushnerUniversity of California, Irvine College of Medicine, California, USAAbstract: Hypoglycemia is a major barrier to achieving glycemic goals in patients with diabetes. Both acute and chronically recurrent hypoglycemic events appear to have long-term consequences for patients with type 2...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Kushner P
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://doaj.org/article/1eca60a17676493fb776e45358fb1ef9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1eca60a17676493fb776e45358fb1ef9
record_format dspace
spelling oai:doaj.org-article:1eca60a17676493fb776e45358fb1ef92021-12-02T00:58:19ZMinimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus1178-7007https://doaj.org/article/1eca60a17676493fb776e45358fb1ef92010-04-01T00:00:00Zhttps://www.dovepress.com/minimizing-the-risk-of-hypoglycemia-in-patients-with-type-2-diabetes-m-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Pamela KushnerUniversity of California, Irvine College of Medicine, California, USAAbstract: Hypoglycemia is a major barrier to achieving glycemic goals in patients with diabetes. Both acute and chronically recurrent hypoglycemic events appear to have long-term consequences for patients with type 2 diabetes mellitus (T2DM). Chronically recurrent hypoglycemia may lead to an impairment of the counterregulatory system, with the potential for the development of hypoglycemia unawareness syndrome, increased severe hypoglycemia-associated hospitalization, and increased mortality. Hypoglycemic events may also have negative implications in cardiovascular disease and/or dementia. Avoidance of hypoglycemia by treating with appropriate, individualized regimens for patients with T2DM should be a primary focus of physicians. Utilizing traditional agents (eg, metformin and thiazolidinediones) that do not promote hypoglycemia, in combination with newer agents such as dipeptidyl peptidase-4 inhibitors and incretin mimetics, could offer a therapeutic advantage when trying to help patients reach their hemoglobin A1c goal without the added risk of hypoglycemia.Keywords: hypoglycemia, type 2 diabetes mellitus, incretin, dipeptidyl peptidase-4 inhibitors, diabetes managementKushner PDove Medical PressarticleHypoglycemiatype 2 diabetes mellitusincretindipeptidyl peptidase-4 inhibitorsdiabetes managementSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 49-53 (2010)
institution DOAJ
collection DOAJ
language EN
topic Hypoglycemia
type 2 diabetes mellitus
incretin
dipeptidyl peptidase-4 inhibitors
diabetes management
Specialties of internal medicine
RC581-951
spellingShingle Hypoglycemia
type 2 diabetes mellitus
incretin
dipeptidyl peptidase-4 inhibitors
diabetes management
Specialties of internal medicine
RC581-951
Kushner P
Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
description Pamela KushnerUniversity of California, Irvine College of Medicine, California, USAAbstract: Hypoglycemia is a major barrier to achieving glycemic goals in patients with diabetes. Both acute and chronically recurrent hypoglycemic events appear to have long-term consequences for patients with type 2 diabetes mellitus (T2DM). Chronically recurrent hypoglycemia may lead to an impairment of the counterregulatory system, with the potential for the development of hypoglycemia unawareness syndrome, increased severe hypoglycemia-associated hospitalization, and increased mortality. Hypoglycemic events may also have negative implications in cardiovascular disease and/or dementia. Avoidance of hypoglycemia by treating with appropriate, individualized regimens for patients with T2DM should be a primary focus of physicians. Utilizing traditional agents (eg, metformin and thiazolidinediones) that do not promote hypoglycemia, in combination with newer agents such as dipeptidyl peptidase-4 inhibitors and incretin mimetics, could offer a therapeutic advantage when trying to help patients reach their hemoglobin A1c goal without the added risk of hypoglycemia.Keywords: hypoglycemia, type 2 diabetes mellitus, incretin, dipeptidyl peptidase-4 inhibitors, diabetes management
format article
author Kushner P
author_facet Kushner P
author_sort Kushner P
title Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
title_short Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
title_full Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
title_fullStr Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
title_full_unstemmed Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
title_sort minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
publisher Dove Medical Press
publishDate 2010
url https://doaj.org/article/1eca60a17676493fb776e45358fb1ef9
work_keys_str_mv AT kushnerp minimizingtheriskofhypoglycemiainpatientswithtype2diabetesmellitus
_version_ 1718403369656123392